Enorama Pharma AB (publ) (ERMA.ST)
SEK 2.13
(-4.05%)
SEK 2.13
(-4.05%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -3.9 Million SEK | -6225.81% |
| 2022 | -616 Thousand SEK | -128.87% |
| 2021 | 2.13 Million SEK | -9.77% |
| 2020 | 2.36 Million SEK | -77.34% |
| 2019 | 10.43 Million SEK | -12.89% |
| 2018 | 11.97 Million SEK | 125.75% |
| 2017 | 5.3 Million SEK | -33.52% |
| 2016 | 7.98 Million SEK | 456.35% |
| 2015 | 1.43 Million SEK | 1.09% |
| 2014 | 1.41 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -6.34 Million SEK | 124.43% |
| 2024 Q1 | -10.03 Million SEK | 10.79% |
| 2023 Q1 | -1.21 Million SEK | -4.12% |
| 2023 Q3 | -990 Thousand SEK | -960.87% |
| 2023 Q2 | 115 Thousand SEK | 109.48% |
| 2023 FY | -38.96 Million SEK | -6225.81% |
| 2023 Q4 | -11.24 Million SEK | -1035.66% |
| 2022 Q3 | 549 Thousand SEK | -12.02% |
| 2022 Q4 | -1.16 Million SEK | -312.2% |
| 2022 FY | -616 Thousand SEK | -128.87% |
| 2022 Q1 | -652 Thousand SEK | 25.82% |
| 2022 Q2 | 624 Thousand SEK | 195.71% |
| 2021 Q3 | 156 Thousand SEK | -86.28% |
| 2021 FY | 2.13 Million SEK | -9.77% |
| 2021 Q4 | -879 Thousand SEK | -663.46% |
| 2021 Q1 | -8000.00 SEK | 99.26% |
| 2021 Q2 | 1.13 Million SEK | 14312.5% |
| 2020 FY | 2.36 Million SEK | -77.34% |
| 2020 Q2 | 2.44 Million SEK | 268.27% |
| 2020 Q1 | 665 Thousand SEK | -93.81% |
| 2020 Q3 | 330 Thousand SEK | -86.53% |
| 2020 Q4 | -1.07 Million SEK | -426.67% |
| 2019 Q3 | -466 Thousand SEK | -134.7% |
| 2019 Q4 | 10.73 Million SEK | 2404.66% |
| 2019 FY | 10.43 Million SEK | -12.89% |
| 2019 Q1 | -1.18 Million SEK | -108.36% |
| 2019 Q2 | 1.34 Million SEK | 213.72% |
| 2018 Q2 | 377 Thousand SEK | 117.57% |
| 2018 FY | 11.97 Million SEK | 125.75% |
| 2018 Q4 | 14.13 Million SEK | 3789.4% |
| 2018 Q3 | -383 Thousand SEK | -201.59% |
| 2018 Q1 | -2.14 Million SEK | -146.18% |
| 2017 Q3 | 216 Thousand SEK | -4.0% |
| 2017 Q1 | 217 Thousand SEK | -93.51% |
| 2017 Q2 | 225 Thousand SEK | 3.69% |
| 2017 FY | 5.3 Million SEK | -33.52% |
| 2017 Q4 | 4.64 Million SEK | 2051.17% |
| 2016 Q1 | -1.17 Million SEK | -181.96% |
| 2016 FY | 7.98 Million SEK | 456.35% |
| 2016 Q4 | 3.34 Million SEK | 1461.41% |
| 2016 Q3 | 214 Thousand SEK | -15.75% |
| 2016 Q2 | 254 Thousand SEK | 121.6% |
| 2015 FY | 1.43 Million SEK | 1.09% |
| 2015 Q2 | - SEK | 100.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | 1.43 Million SEK | 0.0% |
| 2015 Q1 | -614 Thousand SEK | 0.0% |
| 2014 FY | 1.41 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AcuCort AB | 6.59 Million SEK | 159.178% |
| AlzeCure Pharma AB (publ) | -476 Thousand SEK | -719.538% |
| BioGaia AB (publ) | 950.19 Million SEK | 100.411% |
| Enzymatica AB (publ) | 31.86 Million SEK | 112.243% |
| Gabather AB (publ) | - SEK | Infinity% |
| Klaria Pharma Holding AB (publ.) | -9000.00 SEK | -43244.444% |
| Moberg Pharma AB (publ) | -2.09 Million SEK | -85.85% |
| Nanexa AB (publ) | 59.15 Million SEK | 106.594% |
| Newbury Pharmaceuticals AB (publ) | 16.03 Million SEK | 124.331% |
| ODI Pharma AB | -1.34 Million SEK | -190.765% |
| Orexo AB (publ) | 549.9 Million SEK | 100.709% |
| Probi AB (publ) | 220.21 Million SEK | 101.771% |
| Swedencare AB (publ) | 164.8 Million SEK | 102.367% |
| Swedish Orphan Biovitrum AB (publ) | 14.05 Billion SEK | 100.028% |
| Toleranzia AB | -919 Thousand SEK | -324.483% |
| Vivesto AB | -10.65 Million SEK | 63.392% |